Lichtenheldt produces a drug with a novel therapeutic principle for a rare but very serious disease. In preparation for FDA approval under the accelerated procedure as an “orphan drug”, Lichtenheldt was approved by the FDA.
Lichtenheldt produces a drug with a novel therapeutic principle for a rare but very serious disease. In preparation for FDA approval under the accelerated procedure as an “orphan drug”, Lichtenheldt was approved by the FDA.